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Abstract
The association of a drug with its target protein has the effect of blocking the protein activity and is termed a
promiscuous function to distinguish from the protein’s native function (Tawfik and associates, Nat. Genet. 37,
73-6, 2005). Obviously, a protein has not evolved naturally for drug association or drug resistance.
Promiscuous protein functions exhibit unique traits of evolutionary adaptability, or evolvability, which is
dependent on the induction of novel phenotypic traits by a small number of mutations. These mutations
might have small effects on native functions, but large effects on promiscuous function; for example, an
evolving protein could become increasingly drug resistant while maintaining its original function.
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Summary
The association of a drug with its target protein has the effect of blocking the protein activi-
ty and is termed a promiscuous function to distinguish from the protein’s native function
(Tawfik and associates, Nat. Genet. 37, 73-6, 2005).  Obviously, a protein has not evolved nat-
urally for drug association or drug resistance.  Promiscuous protein functions exhibit unique
traits of evolutionary adaptability, or evolvability, which is dependent on the induction of
novel phenotypic traits by a small number of mutations.  These mutations might have small
effects on native functions, but large effects on promiscuous function; for example, an evolv-
ing protein could become increasingly drug resistant while maintaining its original function.
Ariel Fernández, in his opinion piece, notes that drug-binding “promiscuity” can hardly
be dissociated from native functions; a dominant approach to drug discovery is the pro-
tein-native-substrate transition-state mimetic strategy.  Thus, man-made ligands (e.g.
drugs) have been successfully crafted to restrain enzymatic activity by focusing on the
very same structural features that determine the native function.  Using the successful
inhibition of HIV-1 protease as an example, Fernández illustrates how drug designers
have employed naturally evolved features of the protein to suppress its activity.  Based
on these arguments, he dismisses the notion that drug binding is quintessentially promis-
cuous, even though in principle, proteins did not evolve to associate with man made lig-
ands.  In short, Fernández argues that there may not be separate protein domains that one
could term promiscuous domains.
While acknowledging that drugs may bind promiscuously or in a native-like manner a la
Fernández, Tawfik maintains the role of evolutionary adaptation, even when a drug binds
native-like.  In the case of HIV-1 protease, drugs bind natively, and the initial onset of muta-
tions results in drug resistance in addition to a dramatic decline in enzymatic activity and fit-
ness of the virus.  A chain of compensatory mutations follows this, and then the virus
becomes fully fit and drug resistant.
Ben Berkhout and Rogier Sanders subscribe to the evolution of new protein functions
through gene duplication.  With two identical protein domains, one domain can be
released from a constraint imposed by the original function and it is thus free to move in
sequence space toward a new function without loss of the original function.  They empha-
size that the forced evolution of drug-resistance differs significantly from the spontaneous
evolution of an additional protein function.  For instance, the latter process could proceed
gradually on an evolutionary time scale, whereas the acquisition of drug-resistance is an
all or nothing process for a virus, leading to the failure or success of therapy.  They find
no evidence to the thesis that resistance-mutations appear more rapidly in promiscuous
domains than native domains.  Berkhout and Sanders illustrate the genetic plasticity of
HIV-1 by citing examples in which well-conserved amino acid residues of catalytic
domains are forced to mutate under drug-pressure.  HIV drug resistance biology is very
complex.  Instead of a viral protein, a drug can be targeted at a cellular protein.  For exam-
ple, Berkhout and Sanders claim, a drug targeted at the cellular protein CCR5 inhibits the
binding of the viral envelope glycoprotein (Env) to CCR5.  However, Env mutates so that
it binds to the CCR5-drug complex and develops drug resistance.  Interestingly, CCR5 has
not evolved to bind to Env, but to a series of chemokines.
Andrzej Kloczkowski, Taner Sen, and Bob Jernigan point out the importance of protein
motions for binding.  They believe it is likely that different ligands can bind to the diverse
protein conformations sampled in the course of normal protein conformational fluctuations.
They have been applying simple elastic network models to extract the motions as normal
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modes, which yield relatively small numbers of conformations that are useful for develop-
ing protein mechanisms; while these are typically small motions, for some proteins they can
be quite large in scale.  One of the major advantages of the approach is that only relatively
small numbers of modes are important contributors to the overall motion – so the approach
provides a way to systematically map out a protein’s motions.  These models successfully
represent the conformational fluctuations manifested in the crystallographic B-factors, and
often suggest motions related to protein functional behaviors, such as those observed for
reverse transcriptase, where two dominant hinges clearly relate to the processing steps – one
showing anti-correlation between the polymerase and ribonuclease H sites related to the
translation and positioning of the nucleic acid chain, and another for opening and closing the
polymerase site.  Disordered proteins represent a more extreme case where the set of acces-
sible conformations is much larger; thus they could offer up a broader range of possible
binding forms.  Whether evolution controls the functional motions for proteins remains lit-
tle studied.  Intriguingly, buried in the existing databases of protein-protein interactions may
be information that can shed light on the extent of promiscuous binding among proteins
themselves.  Within these data there are cases where large numbers of diverse proteins have
been shown to interact with a single protein; some of these could represent promiscuous pro-
tein-protein binding.  Uncovering these promiscuous behaviors could be important for com-
prehending the details of how proteins can bind promiscuously to one another, and can
exhibit even greater promiscuity in their binding to small molecules.
Most researchers assume a clear delineation between native and promiscuous pro-
tein functions (1).  In contrast with native functions, promiscuous functions are
assumed to involve predominantly entropy-driven interactions, to typically exclude
pair-wise enthalpic contributions, and to be essentially free from selection pressure,
in accord with their purported latency.  Thus, a conspicuous illustration of promis-
cuity is assumed to be enzymatic inhibition by drug association (2-6), a function
for which the protein clearly has not evolved naturally.  I believe this view needs
revision in the light of the following considerations.
There are numerous instances where drug-binding promiscuity can hardly be dis-
sociated from native function, as evidenced by the fact that a dominant approach to
drug discovery is the protein-native-substrate transition-state mimetic strategy (2-
6).  Thus, man-made ligands, for example drug inhibitors, have been successfully
made to inhibit enzymatic activity by focusing on the very same structural features
that determined the native function.
Furthermore, there are native structural features germane to enzymatic processivity
which have been obviously subject to severe selection pressure for a particular role
and are utilized in an alternative role in what Aharoni et al. (1) would call “promis-
cuous” functions.  Thus, promiscuity may engage highly conserved structural
regions of the protein with dual roles, contributing to both a naturally evolved
(native) and a promiscuous function.  For instance, the flexibility of the β-hairpin
flap in HIV-1 protease is required for the processivity of the enzyme (6).  Thus, the
flap region, must have a highly water-exposed – and hence labile – hydrogen bond,
as needed to confer the necessary flexibility associated with the gating mechanism.
A naturally evolved and highly conserved glycine-rich loopy region exposes to
water a backbone hydrogen bond in the β-hairpin.  The over-exposed hydrogen bond
is inherently sticky because it can be strengthened and stabilized upon exogenous
water removal (6-8).  Thus, the lack of protection on the flap backbone hydrogen
bond is subservient to a native function of the HIV-1 protease, but becomes also the
reason for its stickiness, a property taken advantage of in a promiscuous function.  A
proper inhibition of the protease then hinges upon the possibility of wrapping of the
flap hydrogen bonds with the nonpolar groups of the purported drugs (6).
In this way, we are reporting on an instance of a structural feature – a flexible flap
– naturally selected for a purpose and utilized promiscuously for another purpose.
Undeniably, the protein has actually evolved to sustain this feature, thus hinting to
an apparent inconsistency in the views of Aharoni et al. (1), who maintain that
promiscuous functions are not naturally evolved.
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Furthermore, there are naturally evolved and conserved structural features inherent to
catalytic activity that have been used promiscuously by the drug designers aiming at
the inhibition of HIV-1 protease activity.  Thus, there are intramolecularly under-
wrapped or under-dehydrated hydrogen bonds adjacent to the catalytically active site
(Asp25) in each monomer of the functionally compentent homodimer (6).  These
structural features are required to frame an anchoring track for the substrate peptide.
This “sticky track” determined by the under-dehydrated hydrogen bonds is required
to align the substrate peptide chain across the cavity, as needed for selective nucle-
ophilic attack by the two equivalent catalytic Asp25s.  Furthermore, since such bonds
promote the removal of surrounding water (6-8), they enhance the electrostatic field
generated by the catalytic Asp25, by de-screening its net charge.  This is precisely
their raison d’etre: they foster catalytic activity by exacerbating the nucleophilic
potential of Asp25.  On the other hand, since these hydrogen bonds are inherently
sticky for the reasons mentioned above, they have been targeted by drug designers
aiming at inhibiting the protease activity (6).  Thus, drug inhibitors provide inter-
molecular wrapping to these naturally evolved packing defects in the protease
Here we find another instance of naturally evolved features compliant with a native
catalytic function and used promiscuously for drug-based inhibition.  These facts
and the very nature of drug discovery seem to disprove the basic tenet that drug
binding is quintessentially promiscuous because proteins did not evolve to associ-
ate with man-made ligands.  In fact, every native function may be turned promis-
cuous by a sufficiently skillful designer of ligands able to mimic natural substrates
and knowledgeable of the mechanisms of protein associations.  On the other hand,
few native functions may escape promiscuity because exogenous water removal
from pre-formed electrostatics – an entropy-related interaction – is a ubiquitous
determinant of protein associations (7, 8).
References and Footnotes
The article by Fernández (1), and the response that follows, address the following
question: To what extent is drug action – namely the association of a drug with its
target protein, and blocking of the latter’s activity – an inherently promiscuous func-
tion; or could drug binding follow the very same characteristics of the protein’s
native or original activity?  The somewhat colloquial term ‘promiscuity’ is used to
describe the ability of an enzyme or protein to perform functions in addition to those
for which it is evolutionary maintained.  In mechanistic terms, promiscuity can result
from active-site features that are the same, overlapping or distinct to those responsi-
ble for the native function.  Comparison of the two modes – promiscuous vs. native
– has traditionally focused on the differences in the physico-chemical nature of these
interactions.  Recently, we have proposed that there are also evolutionary differences
between the two modes: Promiscuous protein functions seem to exhibit unique traits
of evolutionary adaptability that are distinctly different from those of the native
function (2).  Evolutionary adaptability, or evolvability, is dependent on the induc-
tion of novel phenotypic traits by a small number of mutations.  However, the vast
majority of mutations have deleterious effects on protein function.  How can a pro-
tein resist the deleterious effects of mutations yet maintain the ability to adopt new
functions and structures?  Our results indicated that the evolution of a new function
is underlined by mutations that have little effect on the native function, but large
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effects on the promiscuous functions that serve as starting point.  Thus, an evolving
protein can initially acquire increased fitness towards a new function (e.g., reduced
drug binding) while maintaining its original function.  This despite the fact that both
the promiscuous and the original function take place at the same site (2).
We proposed that the very same mechanism could underline the evolution of drug
resistance.  The binding of drug to its protein target is, by definition, a promiscu-
ous function that competes with the protein’s original or native function – name-
ly the function for which that protein evolved, and has been maintained through-
out.  That drug resistance is a common, and generally harmful, phenomenon is
also beyond dispute.  Once an organism has been exposed to a drug that threatens
its existence, genetic changes often take place in the form of rapidly acquired
mutations that lead to loss of inhibition by the drug, while maintaining the origi-
nal function of the target protein.  We surmise that, mutations that confer drug
resistance exhibit characteristics similar to those of mutations that lead to an
increase in a promiscuous enzymatic function yet do not alter the enzyme’s orig-
inal function.  These mutations are primarily in flexible substrate binding loops,
rather then in the catalytic residues or the protein’s scaffold (2).
The general view regarding promiscuity (e.g., cross-reaction of antibodies, cataly-
sis of non-native substrates by enzymes, et cetera), which is also portrayed in our
article, is that, promiscuity is driven primarily by hydrophobic, and other entropy-
driven interactions (1).  In contrast, binding of the native substrate, or ligand, typ-
ically involves several independent, enthalpy-driven interactions (e.g., hydrogen
bonds).  Our results (2), and numerous records of drug resistance, indicate that,
owing to these differences, mutations that abolish drug binding but preserve the
original function can rise with astonishing ease.  However, as indicated by
Fernández, the above view ignores the fact that, in many cases, drug binding and
the native function overlap to a large extent (1).  In general, the relationship
between specific and promiscuous activities are rarely known.  For example, the
cross-reactivity of antibodies has often been attributed to “hydrophobic stickiness”.
Yet we could show that, several cross-reactants can bind a single antibody while
forming specific hydrogen bonds depending on the particular chemistry of the
cross-reactant and the availability of complimentary antibody residues.
Consequently, close derivatives of these cross-reactants show very low or no bind-
ing, and the cross-reactants exhibit the same degree of specificity as the native lig-
and (3).  Indeed, drug designers often identify highly conserved structural features
that are essential parts of the protein’s active-site (e.g., an enzyme’s catalytic
machinery) and make sure that their drug interacts with these structural elements in
a highly specific manner.  This is the rationale behind the use of transition state
analogs as enzyme inhibitors, or the HIV-1 proteinase inhibitors discussed by
Fernandez (1).  Once a drug interacts with the active-site core and other essential
parts of the protein’s scaffold, it becomes ‘native-like’ in its mode of interaction.
The differences between drugs that are ‘promiscuous’ in their mode of binding, in
oppose to ‘native-like’, can be demonstrated by the completely different patterns
of acquisition of drug resistance observed in response to HIV-1 protease inhibitors
versus reverse transcriptase (RT) inhibitors.  As insightfully described by
Berkhout (4), drug resistance to RT inhibitors follows a simple route whereby one,
or a few, mutations result in an RT variant that resists inhibition but largely main-
tains enzymatic function.  This is precisely the mode of evolutionary adaptation
we described (2).  In contrast, the appearance of drug resistant mutations in the
protease follow the expected negative tradeoff (5), and is, therefore, accompanied
by a dramatic decline in enzymatic activity and in the fitness of the virus.  A long
chain of compensatory mutations follows that restores viral fitness.  Only some of
the mutations actually increase the protease’s activity (and scarcely to a wild-type
level).  Most mutations act indirectly, e.g., through modification of the Gag-pro-
tein cleavage sites that comprise the protease’s substrate, so that virus fitness is
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regained while maintaining drug resistance.  In a simplified manner, the differ-
ences in the way drug resistance evolves can be ascribed to the differences in the
mode of drug binding.  The protease inhibitors generally bind in a ‘native-like’
mode while interacting with the core of the enzyme’s active-site.  But the RT
inhibitors act in a promiscuous mode; they bind to flexible and external parts of
the enzyme that are distant from the core of its active site (4).
In conclusion, in my view, regardless of the mode and strength of interaction, no pro-
tein has evolved to sustain drug binding.  Rather, drug binding may be maintained
‘parasitically’, using conserved features of the protein, but not by contributing to their
evolutionary preservation.  Drug designers can make use of these conserved features,
make their drug ‘go native’, and thereby avoid the rapid emergence of drug resistant
mutants.  Foremost, because a promiscuous function can make use of an active site
conformation that is fundamentally different from the conformation conferring the
original function (6), a drug should make use of the same active-site conformation
used by the native ligand.  In addition, a drug should ideally interact with all the key
active site residues that are used by the protein to perform its original function.  In
both these respects, the identification of lead molecules from combinatorial libraries
is not, in our view, a promising avenue.  This protocol that may generate potent drugs
is likely to lead to a promiscuous rather than native-like mode of binding.  In contrast,
structure-based drug design could ensure that the above requirements are met, and
thereby maximize the overlap between the native function and drug association, and
guarantee that any mutation affecting drug binding is likely to impair the original
function.  In other words, once a drug has been ‘naturalized’, expedition through a
mutation that would otherwise abolish ‘illegitimate’or promiscuous binding, becomes
much more difficult.  To conclude, I would like to note that, the above conclusions are
based on an evolutionary model that only takes into account the target protein, and
ignores a whole variety of other issues, including the pathogenic organism and its
host.  The accompanying commentaries, and works on drug resistant mutants identi-
fied in the clinic (7), reflect the complexity of this problem and its many facets.
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tional protein function.  For instance, the latter process could proceed gradually on
an evolutionary time scale, whereas the acquisition of drug-resistance is an all or
none process for a virus, leading to failure or success of therapy (4).
Fernández (12) argues that there may not be separate protein domains that one
could term promiscuous domains.  Indeed, protein domains without any function
will be lost in evolution, and this will occur surprisingly rapid if we stick to the
HIV-1 example, which is known for its enormous evolutionary speed.
Nevertheless, it is obvious that some domains are more critical than others, and
this is usually reflected in more or less sequence variation when comparing dif-
ferent virus isolates.  Inhibitors of the HIV-1 Reverse Transcriptase (RT) that are
currently used in the clinic represent drugs that target either a promiscuous/more
variable domain (non-nucleoside RT-inhibitor or NNRTI) or the catalytic domain
that executes the native polymerase function (nucleoside RT inhibitor or NRTI).
Although it could a priori have been predicted that resistance-mutations appear
more rapidly in promiscuous domains than native domains, there is no evidence
for this.  For instance, the potent 3TC antiviral is a dNTP-mimic that is incorpo-
rated in the catalytic core, but resistance develops in patients within weeks (10).
More strikingly, the resistance mutation occurs in the absolutely conserved
YMDD motif within the catalytic core, which mutates to YVDD or YIDD (7).
Mutation of this important motif illustrates the genetic plasticity of HIV-1 and
argues that even well-conserved amino acid residues of catalytic domains can be
forced to mutate under drug-pressure.
As argued by Tawfik (13), mutation of a residue within a native domain will more
likely result in a loss of function, and reduced fitness is indeed what is observed for
3TC-resistant viruses (2).  However, reduced viral fitness has also been described
for resistance mutations in less conserved promiscuous domains (6).  There could
be differences in the frequency and magnitude of the fitness loss for drugs that tar-
get native versus promiscuous domains, but such a broad survey has not been per-
formed thus far.  HIV-1 studies also demonstrate the enormous possibilities that are
created by evolution.  Although the initial drug-resistance mutations may reduce
enzyme function, compensatory changes will appear quickly to improve enzyme
function, and the end result may be an enzyme/virus that is more active/fit than the
wild-type (5).  There are more exotic scenario’s, e.g., the appearance of a defective
HIV-1 variant that replicates exclusively in the presence of the antiviral drug (3).
An interesting evolutionary feature of HIV-1 is the switch of the viral envelope
glycoprotein (Env) from usage of CCR5 to CXCR4 as a second receptor in addi-
tion to CD4.  This switch, which requires multiple amino-acid changes, occurs in
about half of the HIV-infected individuals, broadens the host cell range to naïve
CD4+ T cells and is correlated with a more rapid progression to AIDS.  Although
this phenomenon may be related more to cross-reactivity by molecular mimicry
than to promiscuous binding, it follows the path from a highly specialized CCR5-
using Env, via a dual-tropic generalized Env with a relatively low affinity for
either receptor, to another specialized CXCR4-using Env (9).  What is the native
function in such a case?  From a cellular perspective, the native function is bind-
ing of the receptors to their natural ligands; the chemokines RANTES, MIP1-α,
MIP1-β (CCR5) and SDF-1 (CXCR4).  Binding of CCR5 or CXCR4 to Env
would then be parasitic and promiscuous, since these receptors did not evolve to
bind HIV-1 Env.  From the viral perspective, the latter would be the native func-
tion since Env did evolve to use CCR5 or CXCR4.  This CCR5 to CXCR4 switch
also has important implications for drug design and viral resistance.  Several novel
drugs that target the viral entry process are currently under investigation in clini-
cal trials.  Caution is justified with respect to the use of CCR5 inhibitors in the
clinic because they may induce the switch to the more pathogenic CXCR4-using
virus variants.  However, recent evidence indicates that HIV-1 takes another path
of drug resistance, in which Env changes its mode of CCR5-binding (11).  Thus,
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promiscuous binding of the drugs induces a conformational change in CCR5 such
that Env can no longer bind.  Resistance is thought to occur through mutations in
Env that alter the mode of native binding, such that Env is able to bind to the
CCR5-drug complex.  This is a rather unique example because the drug does not
target a viral protein, but a cellular protein.
Finally, Tawfik (13) argues that drug development should preferentially use struc-
ture-based design to yield compounds that bind in the active site of the native
domain, such that escape mutations will impair the original function.  He also argues
that screening of combinational libraries will mostly yield compounds that bind to
promiscuous protein domains, which allows more rapid and easier escape.  We feel
that it is not opportune to close a drug discovery route.  When the target is a virus
like HIV-1, we think that any potent antiviral, no matter how it was developed and
what protein domain it targets, will be a welcome addition to the current arsenal of
antivirals.  In fact, several potent antiretrovirals of the first generation of NNRTI
drugs that are still used successfully in the clinic have been developed by random
screening programs.  Moreover, several of the new and promising inhibitors that are
under investigation in phase II and phase III clinical trials, including some that tar-
get CCR5 or CXCR4, are derived from the screening of combinatorial libraries.
References and Footnotes
The functional dynamics of proteins can be manifested in different ways; in par-
ticular some proteins can bind to multiple ligands in ways that are facilitated by the
intrinsic motions of the protein.  Unstructured proteins could offer some broad
range of structures as alternative binding sites.  Specific binding, in contrast to non-
specific binding, has long been discussed for binding to DNA, but has rarely been
considered for proteins.  Domain swapping offers a particularly interesting exam-
ple of multiple binding states – internally within one monomer, or between two
monomers.  In domain swapping, monomers undergo some internal dissociation,
and form multimeric structures by binding between monomers, often in nearly
identical ways as within the monomeric structure.  Such large scale motions are
seen often in proteins and have recently been shown to be well represented by pro-
tein motion models using simple elastic network models (1).  When the motions are
sufficiently large in scale there are opportunities for different ligands to find favor-
able binding sites at different locations along the motion pathways.  These elastic
models are proving their abilities to represent the important motions in proteins,
and presumably can also offer other opportunities for drug design by targeting
accessible flexible structural sub-states, or interfering with essential hinge motions.
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In a recent paper (2) published in Nature Genetics the research group of Dan
Tawfik has shown that proteins that have evolved to perform a given function often
have the ability to adapt to other, completely unrelated functions as well.  They
have created a speeded-up version of evolution in the lab by introducing random
mutations into the genes encoding various proteins and simulating evolutionary
pressure by selecting mutants with higher levels of activity for one of the promis-
cuous traits.  They were able to significantly increase the activity for which they
were selecting, and found that the levels of the other promiscuous activities in most
cases, dropped dramatically, but in some there was also a significant increase.
Thus, an evolving protein can acquire increased fitness for a new function without
losing its original native function.  Gene duplication and the divergence of a com-
pletely new protein may then follow.  This is a surprising result, since both activi-
ties take place at the exact same site on the enzyme.  According to the authors main-
taining protein native function as well as their responsiveness to mutations for
promiscuous functions are both extremely important for living organisms.  Natural
evolution, leading to native protein functions, takes an extremely long time to
develop.  Promiscuous functions may not have been under selection pressure and
evolution may not have provided for rapid adaptation.  This creates one possible
mechanism for the phenomenon of rapidly developing drug resistance.  A better
understanding of the problem of promiscuity of protein function is extremely
important for progress with drug discovery.  In particular, two problems need to be
resolved – just how ‘promiscuous’ can a protein be in accepting other drug mole-
cules?  And how can drugs be designed to become more specific?  It is likely that
some relevant information might be uncovered from studies of multiple interac-
tions for proteins as collected in the various protein-protein interactions for organ-
isms such as yeast, fruit fly, and worm (3-6).  In other words, functionally impor-
tant promiscuity of binding partners could occur naturally for some proteins.
Ariel Fernández (3) has noted that promiscuous functions cannot be dissociated
from native functions and that structurally conserved binding sites in proteins con-
tribute to both native and promiscuous functions.  Our studies on proteins dynam-
ics lend support to this point of view by suggesting that the motions intrinsic to a
protein could be requisite for the multiple bindings.
Our group and others (1, 7-17) have been studying the effects of collective motions
in proteins.  The main rationale behind this approach is that protein structure deter-
mines its dynamics, and protein dynamics is a key factor in the determination of pro-
tein function.  In the past we have studied for example the relationships between the
structure, functional mechanism and collective motions of the HIV-1 reverse tran-
scriptase (RT) by using the Gaussian network model (GNM) of proteins (10, 11, 18).
This model is particularly suitable for elucidating the global dynamic characteristics
of large proteins such as the heterodimeric RT comprising a total of 982 residues.
By treating the macromolecule as a coarse-grained uniform block of material, uti-
lizing only the Cα positions, the normal modes of motion can be obtained.  Local
packing density and coordination order of amino acid residues was found to deter-
mine the type and range of motions, both at the residue level and on a global scale,
such as the correlated movements of entire subdomains.  Of the two subunits, p66
and p51, forming the RT, only p66 has a DNA-binding cleft and a functional poly-
merase active site.  This difference in the structure of the two subunits is reflected
in their dynamic characteristics: only p66 has the potential to undergo its large-scale
cooperative motions in the heterodimer, while p51 is essentially rigid.  Taken togeth-
er, the global motion of the RT heterodimer is comprised of movements of the p66
thumb subdomain perpendicular to those of the p66 fingers, accompanied by anti-
correlated fluctuations of the RNase H domain and p51 thumb, thus providing
details of the processivity mechanism.  A few clusters of residues, generally distant
in sequence but close in space, are identified in the p66 palm and connection sub-
domains to form the hinge-bending regions that control the highly concerted motion
of the subdomains.  These regions include the catalytically active site and the non-
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nucleoside inhibitor binding pocket of p66 polymerase, as well as sites whose muta-
tions have been shown to impair enzyme activity.  It is easily conceivable that this
hinge region, indicated by GNM analysis to play a critical role in modulating the
global motion, is locked into an inactive conformation upon binding of an inhibitor.
Bahar et al. have shown that some inhibitors can change the directions of the intrin-
sic motions (18).  Comparative analyses of the dynamic characteristics of the unli-
ganded and liganded dimers indicate severe repression of the mobility of the p66
thumb in RT’s global mode, upon binding of non-nucleotide inhibitors.
Our most recent results obtained for transmembrane proteins further support the
hypothesis of the strong interconnection between structure, dynamics and protein
function (19).  E. coli requires an efficient signaling and transport system to suc-
cessfully sequester iron from its environment.  FecA, a transmembrane protein,
serves a dual role.  It binds iron in the form of ferric citrate and initiates a signaling
pathway which results in the transcription of several iron transporter genes.  FecA
interacts with several intracellular membrane proteins to perform these tasks.  We
combined the predicted structure of the NH2-terminal domain (with A. Kolinski)
with the plug and the barrel domains and applied elastic network models to derive
global modes of motion of the FecA protein (Fig. 1) and obtained high correlation
with the experimental B-factors.  The FecA global motions derived from normal
modes show various motions in the NH2-terminal domain relative to the plug and
the barrel domains, which are anchored in the membrane.  These motions are illus-
trated in Figure 1 with arrows.  In the slowest mode, the NH2-terminal domain
swings towards the right side, approaching the periplasmic loops.  In the second
slowest mode, the NH2-terminal domain swings to the right, interacting with the
loops located on that side.  Our analysis of the motion in the plug and barrels shows
that these periplasmic loops are also highly mobile, and that the NH2-terminal
domain may interact with these loops.  In the third slowest motion, the NH2-termi-
nal domain pulls out from the barrel.  In the fourth slowest motion, the NH2 domain
twists sideways.  And, in the fifth slowest mode, the NH2-terminal domain rotates
slightly to the right, a motion hindered by the coil region connecting the NH2-ter-
minal domain to the plug domain.  The last three motions may be useful to ensure
flexibility when FecA is interacting in a complex or to reduce energy barriers during
protein-protein binding.  Since the slowest modes play a dominant role in determin-
ing a protein’s functional mechanism, FecA may employ a single slow mode, or a
combination of modes to activate diverse pathways in the signaling and transporting
of iron in the form of ferric citrate.  This is a remarkable example that can explain
how information is transferred from the extracellular to the periplasmic side and how
ferric citrate binding to the extracellular loops can activate different motion patterns
in the periplasmic NH2-terminal domain.  Binding does not alter the normal motions
of the NH2-terminal domain, but influences the combination of these modes affect-
ing FecA’s coupled activation/deactivation signaling ability.  Evolution could exploit
the large number of combinations of such motions to redefine a protein’s function.
From this perspective, the native and promiscuous functions are just different com-
binations of the same group of motions as, differentially favored during evolution.
Elastic network models have proven themselves in characterizing the important
pathways dictated by a protein’s structure, which means that they will also be use-
ful for deriving structures deviating from the known native structure, and conse-
quently can be an important tools for characterizing promiscuous binding, includ-
ing those variable sites important for drug design.
Reference and Footnotes
623
Protein Promiscuity
Figure 1: Representation of FecA protein and its major
motions.  The NH2-terminal domain is modeled using
ab initio and is located in the periplasm under the plug
and the barrel domains.  The arrows illustrate the pre-
dicted global motion directions in the slowest modes.  1
represents the slowest mode, 2 the second slowest mode
etc.  The directional information of the 4th slowest mode
is provided in the text.
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